{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Sclerosis+With+Lung+Involvement",
    "query": {
      "condition": "Systemic Sclerosis With Lung Involvement"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T00:51:54.768Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06329401",
      "title": "A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Fibrosis",
        "Progressive Pulmonary Fibrosis",
        "Pulmonary Fibrosis Secondary to Systemic Sclerosis",
        "Pulmonary Fibrosis, Interstitial Lung Disease",
        "Interstitial Lung Disease",
        "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",
        "Interstitial Lung Disease in Patients With Rheumatoid Arthritis",
        "Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere",
        "Hypersensitivity Pneumonitis",
        "Interstitial Lung Disease With Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "AP01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Avalyn Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2024-04-03",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-23T00:51:54.768Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06329401"
    },
    {
      "nct_id": "NCT04837131",
      "title": "A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma",
        "Diffuse Systemic Sclerosis",
        "Diffuse Scleroderma",
        "Diffuse Cutaneous Systemic Sclerosis",
        "Diffuse Cutaneous Scleroderma",
        "Progressive Systemic Sclerosis",
        "Progressive Scleroderma",
        "Scleroderma, Systemic",
        "Scleroderma, Diffuse",
        "Scleroderma;Progressive",
        "Systemic Sclerosis, Diffuse",
        "Systemic; Sclerosis, Progressive",
        "Scleroderma of Lung",
        "Scleroderma With Pulmonary Involvement",
        "Systemic Sclerosis Pulmonary",
        "Systemic Sclerosis With Lung Involvement",
        "Interstitial Lung Disease",
        "Pulmonary Fibrosis Interstitial"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael M. Pham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-04-28",
      "completion_date": "2024-02-23",
      "has_results": true,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-07-23T00:51:54.768Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837131"
    },
    {
      "nct_id": "NCT05785624",
      "title": "A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Systemic Sclerosis With Lung Involvement"
      ],
      "interventions": [
        {
          "name": "Vixarelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 286,
      "start_date": "2023-05-26",
      "completion_date": "2026-01-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-07-23T00:51:54.768Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05785624"
    },
    {
      "nct_id": "NCT01758250",
      "title": "Microvascular and Fibrosis Imaging Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autoimmune Diseases",
        "Sickle Cell Disease",
        "Chronic Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Acoustic Radiation Force Impulse (ARFI)",
          "type": "OTHER"
        },
        {
          "name": "Laser Doppler Flowmetry (LDF)",
          "type": "OTHER"
        },
        {
          "name": "Laser Doppler Perfusion Imaging (LDI)",
          "type": "OTHER"
        },
        {
          "name": "Optical Coherence Tomography (OCT)",
          "type": "OTHER"
        },
        {
          "name": "Orthogonal Polarization Spectral Imaging (OPSI)",
          "type": "OTHER"
        },
        {
          "name": "Nail fold video capillaroscopy (NVC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2013-02",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-07-23T00:51:54.768Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01758250"
    },
    {
      "nct_id": "NCT01257802",
      "title": "GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic",
        "Systemic Vasculitis",
        "Isolated Angiitis of Central Nervous System",
        "Lung Disease With Systemic Sclerosis",
        "Lung Disease Interstitial Diffuse"
      ],
      "interventions": [
        {
          "name": "depot leuprolide acetate 3.75 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph Mccune",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 14,
      "start_date": "2011-05",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-27",
      "last_synced_at": "2026-07-23T00:51:54.768Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257802"
    },
    {
      "nct_id": "NCT00333437",
      "title": "Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 7,
      "start_date": "2006-05",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2013-11-13",
      "last_synced_at": "2026-07-23T00:51:54.768Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333437"
    }
  ]
}